WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinomaRosa A. van Amerongen, Mirjam H.M. Heemskerk|Journal for ImmunoTherapy of Cancer|2022Cited by 23
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancerRosa A. van Amerongen, Mirjam H.M. Heemskerk|Frontiers in Immunology|2023Cited by 21
Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potentialRosa A. van Amerongen, Mirjam H.M. Heemskerk|Molecular Therapy — Methods & Clinical Development|2023Cited by 15